Phase II Trial of M-AMSA in Hepatocellular Carcinoma: a Southwest Oncology Group Study

Overview

Journal Cancer Treat Rep

Specialty Oncology

Date 1982 Aug 1

PMID 6286120

Citations 4

Authors

R M Bukowski

S Legha

J Saiki

H J Eyre

R OBryan

Affiliations

Soon will be listed here.

Abstract

Twenty-three patients with heptocellular carcinoma were treated with m-AMSA at a dose of 120 mg/m2 iv repeated at 4-week intervals. Toxicity was primarily hematologic. Partial responses occurred in two of 14 previously treated patients and in one of nine previously untreated patients. The overall activity of m-AMSA in patients with hepatocellular carcinoma appears minimal.

Citing Articles

Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits.

Paxton J, Jurlina J Cancer Chemother Pharmacol. 1986; 16(3):253-6.

PMID: 3754493 DOI: 10.1007/BF00293987.

Dose-dependent pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in rabbits.

Paxton J, Evans P, Singh R Cancer Chemother Pharmacol. 1987; 20(1):13-5.

PMID: 3621447 DOI: 10.1007/BF00252952.

The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4 -acridinecarboxamide (CI-921) in a phase 1 trial.

Paxton J, Hardy J, Evans P, Harvey V, Baguley B Cancer Chemother Pharmacol. 1988; 22(3):235-40.

PMID: 3409457 DOI: 10.1007/BF00273417.

The effect of cimetidine, phenobarbitone and buthionine sulphoximine on the disposition of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in the rabbit.

Paxton J, Evans P, Hardy J Cancer Chemother Pharmacol. 1989; 23(5):291-5.

PMID: 2706733 DOI: 10.1007/BF00292406.